title: In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
abstract: OBJECTIVE
  To evaluate bropirimine for in vivo activity in rodent prostate cancer.
  
  
  METHODS
  Subcutaneously injected PAIII and Dunning MAT-LyLu rodent prostate cancer cells caused solid tumors and death in controls. Bropirimine was given on varying schedules at 250 mg./kg. by gavage, and tumor volume and survival were recorded.
  
  
  RESULTS
  Bropirimine prevented growth when given on the day of tumor injection and caused 95% of advanced tumors to regress completely in the PAIII model. Bropirimine caused significant growth inhibition and prolongation of survival in the MAT-LyLu model.
  
  
  CONCLUSIONS
  Bropirimine has statistically significant in vivo activity against both of these rodent prostate cancer cell lines.
authors.affiliation: Division of Urology, University of Texas Health Science Center at San Antonio 78284-7845, USA.
authors.forename: M F
authors.initials: MF
authors.lastname: Sarosdy
authors.forename: A L
authors.initials: AL
authors.lastname: Higdon
authors.forename: C A
authors.initials: CA
authors.lastname: Demoor
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D003596:Cytosine; C033560:bropirimine